



bioMérieux – Third-Quarter 2025 Business Review

- ▾ **7.3% organic sales growth in the first nine months of the year, fully in line with annual guidance**, with sales reaching a total of €2,992m, primarily driven by a 9% organic increase across the four growth drivers of the GO•28 strategic plan:
 - **BIOFIRE®¹ non-respiratory panels** recorded a 10% organic sales growth, driven by increase in all panels and a sustained installed base expansion;
 - **SPOTFIRE®²** continued its strong growth trajectory with 114% organic sales increase year on year. The pace of instrument installations accelerated in Q3, with over 900 new instruments, bringing the total installed base to more than 5,500 instruments at the end of September more than doubling over 12 months (+160%);
 - **Microbiology** organic sales growth reached 5% excluding China, while the overall performance (+3%) was impacted by a double-digit decline in China;
 - **Industrial Applications:** strong dynamic with a 10% organic sales increase, driven by 15% organic sales growth in the Pharma Quality Control segment leveraging on new products launches (molecular range, 3P® ENTERPRISE);
- ▾ **BIOFIRE® respiratory panels** sales rose by 6% organically, reflecting a strong epidemiological activity in Q1 and lower levels in Q2 and Q3.
- ▾ **3% organic sales growth in Q3 impacted by continuous mid-teens decrease in China and an 8% decline in BIOFIRE® Respiratory Panels (low epidemiology).** Excluding those two elements, Q3 performance stands at +7.6%.
- ▾ **2025 full year guidance:**
 - **Sales are now expected to grow between +5.5% and +6.5%** at constant exchange rates (versus between +6% and +7.5% previously) on a late respiratory season.
 - **Confirmation of the expected +12% to +18% growth in contributive operating income before non-recurring items (CEBIT)³** at constant exchange rates, based on a nine months profitability fully aligned with the GO•28 trajectory.
 - **The currency effect³ is expected to have a negative impact in the range of around - €30m** on the 2025 annual CEBIT versus around -€25m previously.

Pierre Boulud, Chief Executive Officer, said: *"In a context of low epidemiological activity, we continue to expand our installed base, particularly for BIOFIRE® and SPOTFIRE®, at a faster pace than in 2024, building a strong platform for growth for the coming years. At the same time, bioMérieux continues to deliver on its GO•28 ambition, with significant profitability improvement and sustained innovation through several product launches since the start of the year."*

¹ In this press release BIOFIRE® refers to BIOFIRE® FILMARRAY® TORCH system and panels

² In this press release SPOTFIRE® refers to BIOFIRE® SPOTFIRE® system and panels

³ As defined in Appendix #3

Marcy l'Étoile, France, November 4, 2025 – bioMérieux, a world leader in the field of *in vitro* diagnostics, today releases its business review for the nine months ended September 30, 2025.

SALES

Unless otherwise stated, sales growth is expressed at constant exchange rates and scope of consolidation (like-for-like).

Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported. Organic growth (at constant exchange rates and scope of consolidation) reached +7.3% for the first nine months of the year. The currency effect had a negative €85 million impact on sales over 9 months, due to the appreciation of the euro against most of the currencies and notably the US dollar, the Argentinian peso, the Mexican peso and the Turkish lira.

Analysis of sales

In € millions

SALES - NINE MONTHS ENDED SEPTEMBER 30, 2024	2,871	
Currency effect	-85	-3.0%
Changes in scope of consolidation ⁴ & hyperinflation ⁵	-3	-0.1%
Organic growth (at constant exchange rates and scope of consolidation)	+209	+7.3%
SALES - NINE MONTHS ENDED SEPTEMBER 30, 2025	2,992	+4.2%

ANALYSIS OF SALES BY APPLICATION

Sales by Application In € millions	Q3 2025	Q3 2024	% change as reported	% change at constant exchange rates and scope of consolidation	9 months ended Sept. 30, 2025	9 months ended Sept. 30, 2024	% change as reported	% change at constant exchange rates and scope of consolidation
Clinical Applications	793.4	820.8	-3.3%	+2.1%	2,517.8	2,427.1	+3.7%	+6.9%
Molecular biology	370.6	379.4	-2.3%	+4.0%	1,273.3	1,154.0	+10.3%	+13.4%
BIOFIRE®	326.6	345.8	-5.6%	+0.6%	1,121.6	1,058.9	+5.9%	+8.9%
SPOTFIRE®	31.4	20.4	+54.5%	+65.7%	110.8	53.1	+108.9%	+113.7%
Other Molecular	12.6	13.2	-4.4%	-0.5%	40.9	42.0	-2.7%	-0.6%
Microbiology	334.5	342.4	-2.3%	+2.2%	981.0	980.8	+0.0%	+2.9%
Immunoassays	75.9	86.3	-12.1%	-8.0%	225.1	254.9	-11.7%	-8.9%
Other lines ⁽¹⁾	12.4	12.7	-2.2%	+8.4%	38.3	37.4	+2.4%	+19.1%
Industrial Applications⁽²⁾	154.7	147.9	+4.6%	+9.1%	474.1	443.5	+6.9%	+9.5%
TOTAL SALES	948.1	968.7	-2.1%	+3.1%	2,991.9	2,870.6	+4.2%	+7.3%

(1) Including mainly BioFire Defense, R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

Q3 25 vs Q3 24 like-for-like trends per applications:

- ▾ **Clinical Applications** sales (84% of total sales), increased by 2% over the quarter:
 - In **molecular biology**:
 - BIOFIRE® non-respiratory panels sales increased by 9%, supported by solid growth in EMEA (Europe, Middle East, Africa) and Latin America, while the US and Asia Pacific performances were slower due to flat sales of the Pneumonia panel, reflecting moderate respiratory activity over the quarter;

⁴ As defined in Appendix #2.

⁵ For those currencies meeting the criteria to be considered hyperinflationary under IAS 29, such as Argentina and Turkey, an IFRS technical adjustment for hyperinflation impact is reflected as FX and therefore excluded from the organic growth calculation. The effect of operational actions taken in these countries such as increased pricing to mitigate the inflationary impact is reflected as part of the organic growth

- BIOFIRE® respiratory panels sales declined 8%, impacted by a lower circulation of respiratory pathogens compared to the same quarter in 2024;
- Continued BIOFIRE® installed base expansion over the quarter, largely above the number of net installations in Q3 2024;
- SPOTFIRE® sales amounted to €31m in the quarter, an increase of +66% in the context of a low respiratory epidemiology. More than 900 instruments were installed in the quarter, a significant acceleration compared to Q3 24 (600 installations), leading to a total installed base of more than 5,500 instruments at the end of September 2025 (+160% over the last 12 months).
- In **microbiology**, sales increased by 2% impacted by a decline in China due to an unfavorable local healthcare spending trend. Excluding China, microbiology grew by 4% over the quarter on a high year-on-year comparison basis, with reagent sales up 12% in Q3 2024.
- In **immunoassays**, sales declined by 8%, under the combined effect of the drop in the Chinese market, impacted by the implementation of the local volume-based procurement policy, and the continuous decline in global VIDAS® PCT sales (17% of total immunoassays sales). The rest of the VIDAS® business was stable.
- **Industrial Applications** sales (16% of total sales), delivered a solid organic growth of over 9%, driven primarily by the Pharma Quality Control segment up +15%. This performance was notably supported by a strong momentum in recently launched products in the cytometry and molecular ranges.

ANALYSIS OF SALES BY REGION

Sales by Region In € millions	Q3 2025	Q3 2024	% change as reported	% change at constant exchange rates and scope of consolidation	9 months ended Sept. 30, 2025	9 months ended Sept. 30, 2024	% change as reported	% change at constant exchange rates and scope of consolidation
North America	411.9	426.9	-3.5%	+3.6%	1,371.2	1,272.3	+7.8%	+11.0%
Latin America	66.0	63.6	+3.8%	+15.7%	195.9	189.5	+3.4%	+16.7%
EMEA ⁽¹⁾	319.6	309.5	+3.3%	+4.1%	957.3	925.1	+3.5%	+4.2%
Asia Pacific	150.6	168.8	-10.8%	-4.6%	467.4	483.7	-3.4%	-0.1%
TOTAL SALES	948.1	968.7	-2.1%	+3.1%	2,991.9	2,870.6	+4.2%	+7.3%

⁽¹⁾ Europe, the Middle East and Africa

Q3 25 vs Q3 24 like-for-like trends per region:

- In **North America** (43% of the consolidated total), revenue grew by 4%, driven by a double-digit growth in industrial applications and a 6% increase in microbiology. This performance was partly offset by a decline in BIOFIRE® respiratory panels sales, in a context of low epidemiological activity.
- In **Latin America** (7% of the consolidated total), the quarterly growth reached 16% (+11% excluding Argentina – hyperinflation country), thanks to a strong momentum in BIOFIRE® panels sales and a double-digit growth in microbiology and industrial applications.
- Sales in the **Europe – Middle East – Africa** region (34% of the consolidated total) came to €320 million for the quarter, up 4% year-on-year, driven by close to 20% sales growth in BIOFIRE® non respiratory panels and a double digit increase in industrial applications sales while BIOFIRE® respiratory panels sales declined mid-teens as a result of a significantly lower epidemiological activity compared to 2024.
- Sales in the **Asia Pacific** region (16% of the consolidated total) amounted to €151 million for the third quarter of 2025, down 5% from the prior-year period. Excluding China, sales were up 4%, led by the

success of SPOTFIRE® in Japan and a double-digit sales growth of BIOFIRE® non-respiratory panels while BIOFIRE® respiratory panels sales were significantly down.

EVENTS OF THIRD-QUARTER 2025

- ▶ **bioMérieux receives U.S. 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini**

On August 18, 2025, bioMérieux announced that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a validated specimen type for this panel, specifically for use with the respiratory test menu. By swabbing only the anterior part of the nasal cavity, ANS provides significantly more comfort for the patient.

- ▶ **bioMérieux develops game changing Quality Control solution GENE-UP® PRO HRM**

On August 5, 2025, bioMérieux announced the launch of GENE-UP® PRO HRM—the first DNA-based test commercially developed to detect heat-resistant molds at the molecular level. Developed in partnership with historic brand Ocean Spray Cranberries, Inc., the game-changing testing innovation can accurately identify the presence of viable heat-resistant molds and provides a significantly shorter time-to-result, reducing the current Compendial Method 15-day result time down to only 72 hours.

- ▶ **bioMérieux recognized for Best System Performance and Best Service with 2025 IMV ServiceTrak™ Clinical Laboratory Awards**

On August 5, 2025, bioMérieux received two 2025 IMV ServiceTrak™ Clinical Laboratory Awards for excellence in Immunoassay. These awards highlight bioMérieux's continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories.

INVESTOR PRESENTATION

bioMérieux will hold an investor call on Tuesday, November 4, 2025 at 2:30 pm Paris time (GMT+1). The call will be conducted in English and will be accessible via webcast.

Webcast link: : <https://biomerieux.engagestream.companywebcast.com/2025-11-04-q3>

For people unable to join the webcast URL, please register to the audio conference through the link below

Audio conference link: <https://engagestream.companywebcast.com/biomerieux/2025-11-04-q3/dial-in>

INVESTOR CALENDAR

Fourth-quarter 2025 sales and 2025 financial results

February 27, 2026

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4.0 billion, with over 93% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com

CONTACTS

Investor Relations

bioMérieux

Aymeric Fichet

Tel.: +33 (0)4 78 87 20 00

investor.relations@biomerieux.com

Media Relations

bioMérieux

Romain Duchez

Tel.: +33 (0)4 78 87 20 00

media@biomerieux.com

France

Isabelle de Segonzac (Image 7)

Tel.: +33 (0)1 53 70 74 64

isegonzac@image7.fr

PRESS RELEASE

APPENDIX 1: QUARTERLY SALES DETAILS

Sales by Application in € millions and % Change in Sales by Application

	First quarter		Second quarter		Third quarter		9 months	
	2025	2024	2025	2024	2025	2024	2025	2024
Clinical applications	937.8	818.7	786.6	787.6	793.4	820.8	2,517.8	2,427.1
Molecular biology	521.7	409.6	380.9	365.1	370.6	379.4	1,273.3	1,154.0
BIOFIRE®	452.3	374.8	342.8	338.4	326.6	345.8	1,121.6	1,058.9
SPOTFIRE®	54.3	19.9	25.1	12.8	31.4	20.4	110.8	53.1
Other Molecular	15.2	14.8	13.0	14.0	12.6	13.2	40.9	42.0
Microbiology	326.1	314.2	320.4	324.2	334.5	342.4	981.0	980.8
Immunoassays	75.0	83.3	74.2	85.2	75.9	86.3	225.1	254.9
Other lines ⁽¹⁾	14.9	11.6	11.1	13.1	12.4	12.7	38.3	37.4
Industrial Applications⁽²⁾	160.1	146.5	159.3	149.1	154.7	147.9	474.1	443.5
TOTAL SALES	1,097.9	965.2	945.9	936.7	948.1	968.7	2,991.9	2,870.6

(1) Including mainly BioFire Defense and R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

	First quarter		Second quarter		Third quarter		9 months	
	As reported	Like-for-like ⁽³⁾	As reported	Like-for-like ⁽³⁾	As reported	Like-for-like ⁽³⁾	As reported	Like-for-like ⁽³⁾
Clinical applications	+14.5%	+13.3%	-0.1%	+5.2%	-3.3%	+2.1%	+3.7%	+6.9%
Molecular biology	+27.4%	+24.7%	+4.3%	+10.4%	-2.3%	+4.0%	+10.3%	+13.4%
BIOFIRE®	+20.7%	+18.1%	+1.3%	+7.3%	-5.6%	+0.6%	+5.9%	+8.9%
SPOTFIRE®	+172.0%	+165.7%	+96.8%	+108.7%	+54.5%	+65.7%	+108.9%	+113.7%
Other Molecular	+2.7%	+2.2%	-6.7%	-3.7%	-4.4%	-0.5%	-2.7%	-0.6%
Microbiology	+3.8%	+3.8%	-1.2%	+2.8%	-2.3%	+2.2%	+0.0%	+2.9%
Immunoassays	-10.0%	-9.4%	-12.9%	-9.2%	-12.1%	-8.0%	-11.7%	-8.9%
Other lines ⁽¹⁾	+28.4%	+33.8%	-15.9%	+17.0%	-2.2%	+8.4%	+2.4%	+19.1%
Industrial Applications⁽²⁾	+9.3%	+9.0%	+6.8%	+10.5%	+4.6%	+9.1%	+6.9%	+9.5%
TOTAL SALES	+13.7%	+12.7%	+1.0%	+6.1%	-2.1%	+3.1%	+4.2%	+7.3%

(1) Including mainly BioFire Defense and R&D-related revenue arising on clinical applications

(2) Including R&D-related revenue arising on industrial applications.

(3) At constant exchange rates and scope of consolidation.

Sales by Region in € millions and % Change in Sales by Region

	First quarter		Second quarter		Third quarter		9 months	
	2025	2024	2025	2024	2025	2024	2025	2024
North America	543.7	442.5	416.4	402.9	411.9	426.9	1,371.2	1,272.3
Latin America	62.6	59.9	66.5	66.1	66.0	63.6	195.9	189.5
Europe ⁽¹⁾	320.7	303.4	317.0	312.2	319.6	309.5	957.3	925.1
Asia Pacific	170.8	159.4	146.0	155.5	150.6	168.8	467.4	483.7
TOTAL SALES	1,097.9	965.2	945.9	936.7	948.1	968.7	2,991.9	2,870.6

(1) Including the Middle East and Africa.

	First quarter		Second quarter		Third quarter		9 months	
	As reported	Like-for-like ⁽³⁾	As reported	Like-for-like ⁽³⁾	As reported	Like-for-like ⁽³⁾	As reported	Like-for-like ⁽³⁾
North America	+22.9%	+19.3%	+3.3%	+10.0%	-3.5%	+3.6%	+7.8%	+11.0%
Latin America	+4.6%	+14.0%	+0.7%	+18.9%	+3.8%	+15.7%	+3.4%	+16.7%
Europe ⁽¹⁾	+5.7%	+5.9%	+1.5%	+2.5%	+3.3%	+4.1%	+3.5%	+4.2%
Asia Pacific	+7.1%	+6.7%	-6.1%	-2.2%	-10.8%	-4.6%	-3.4%	-0.1%
TOTAL SALES	+13.7%	+12.7%	+1.0%	+6.1%	-2.1%	+3.1%	+4.2%	+7.3%

(1) Including the Middle East and Africa. (2) At constant exchange rates and scope of consolidation.

APPENDIX 2: GLOSSARY & DISCLAIMER

DEFINITIONS

Changes in the scope of consolidation:

The effects of changes in the scope of consolidation are determined:

- for acquisitions for the period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the period by the entities acquired from their entry into the scope of consolidation;
- for acquisitions of the previous period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the months in which the acquired entities were not consolidated during the previous period;
- for disposals for the period by adding to sales and operating expenses for the period the amount of sales and operating expenses made by the entities sold the previous period, during the months in which these entities are no longer consolidated over the current period;
- for disposals for the previous period, by adding to the sales and operating expenses of the period the sales and operating expenses made during the preceding period by the entities sold.

Currency effect: established by comparing the actual numbers converted at the average exchange rates of the current year to the actual numbers converted at the average exchange rates of the comparison period. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up.

Contributive operating income before non-recurring items (CEBIT): operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs. The Company considers that this indicator provides the best possible representation of the operational performance of the Company. The reconciliation between the operating income before non-recurring items and the contributive operating income before non-recurring items is presented in note #24 of the June 30th 2025 financial report.

DISCLAIMER

The forward-looking statements contained in this document are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2024 Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.